Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs SNY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SNY Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 7–3 Matrix Metrics)

SNY Overall Winner 6-Pillar Tally: TAK 0 – 5 SNY (1 Tie) Matrix Metrics: TAK 3 – 7 SNY

As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas SNY carries 31.7/100 (SELL) at $48.47 (8.9x Forward P/E, 22.3% operating margin).

  • Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. 16.6% operating margin) and revenue trajectory (+15.7% vs. +6.7% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs SNY
TAK NYSE
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
SNY NASDAQ Head-to-Head Winner
Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
Pharmaceutical Preparations
$48.47
+0.21% 1D
Market Cap $116.0B
TTM Revenue $30.0B
Forward P/E 8.9x
Beta / 30D Vol 0.20β · 27% Vol
Unified Composite Score
31.7 / 100 SELL
Tech 50.0 Fund 28.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 77
RSI-14: 77.5 · SMA20: $45.10 · SMA50: $42.77

6-Pillar Scorecard Institutional Category Breakdown (TAK 0 – 5 SNY)

Columns: Metric · TAK · SNY
1. Valuation Multiples SNY
Forward P/E 12.7x 8.9x
Trailing P/E N/M 24.1x
PEG Ratio 0.47x 1.76x
EV / Revenue 2.6x 3.9x
2. Growth & Scale SNY
Revenue Growth (YoY) +6.7% +15.7%
Earnings Growth (YoY) -9.8% +9.4%
TTM Revenue (USD) $25.7B $30.0B
Market Cap $67.5B $116.0B
3. Profitability & Quality SNY
Gross Margin 64.8% 74.3%
Operating Margin 16.6% 22.3%
Net Profit Margin 0.9% 8.2%
Return on Equity (ROE) 0.6% 5.7%
4. Balance Sheet & Cash Flow SNY
Cash Generation (TTM) $7.48B EBITDA $8.70B EBITDA
Cash Flow Margin 29.1% EBITDA Mgn 29.0% EBITDA Mgn
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $34.11 Book/Sh · 5.7% ROE
Dividend Yield 2.92% None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 22.4% (5th %ile) 22.0% (43rd %ile)
Put/Call OI Skew Thin ADR Chain Thin ADR Chain
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat SNY
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 52.0% of Rev ($15.6B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (3) vs SNY (7)
Institutional Metric TAK SNY Criterion Row Edge
Market Capitalization
Scale
$67.5B $116.0B Larger Scale SNY
Trailing P/E Ratio
Valuation
N/M 24.1x Lower Multiple SNY
Forward P/E Ratio
Valuation
12.7x 8.9x Lower Multiple SNY
Revenue Growth (YoY)
Growth
+6.7% +15.7% Higher Growth SNY
Operating Margin (TTM)
Profitability
16.6% 22.3% Higher Margin SNY
Net Profit Margin
Profitability
0.9% 8.2% Higher Margin SNY
Return on Equity (ROE)
Capital Efficiency
0.6% 5.7% Higher ROE SNY
52-Week Range Position
Momentum
97% ($14–$22) 69% ($39–$53) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 0.20β · 27% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 31.7 / 100 (SELL) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $30.0B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 74.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 1.76x PEG · 3.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $8.70B EBITDA ($34.11 Book/Sh · 5.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SNY +9.46 pp
TAK: +9.89% · SNY: +19.35%
3M Horizon TAK +11.97 pp
TAK: +19.75% · SNY: +7.78%
6M Horizon TAK +19.13 pp
TAK: +30.45% · SNY: +11.32%
1Y Horizon TAK +59.18 pp
TAK: +51.79% · SNY: -7.39%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs SNY. Trailing 12-month operating profitability (TAK 16.6% vs SNY 22.3%) and valuation multiples (TAK 12.7x vs SNY 8.9x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
SNY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$30.0B
Gross Margin74.3%
Op. Margin22.3%
ROE / Fwd P/E5.7% · 8.9x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SNY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.0%
IV Percentile 43rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SNY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
SNY Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $116.0B market capitalization and 22.3% operating margin.
OpEx & R&D Reinvestment 52.0% of Rev ($15.6B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs SNY Key Questions & Quantitative Answers

As of Nov 16, 2026, Sanofi (SNY) is the stronger overall head-to-head candidate over Takeda Pharmaceutical Company Limited (TAK) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas SNY carries 31.7/100 (SELL) at $48.47 (8.9x Forward P/E, 22.3% operating margin). Composite vs. Pillar Nuance: While TAK currently prints a higher short-term Unified Composite Score (47.7/100 HOLD vs. SNY 31.7/100 SELL), SNY captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (22.3% vs. 16.6% operating margin) and revenue trajectory (+15.7% vs. +6.7% YoY).

SNY leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with SNY at +15.7% YoY revenue growth and +9.4% YoY earnings growth on $30.0B TTM revenue (74.3% gross margin, 22.3% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $30.0B for SNY. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 52.0% of Rev ($15.6B) (0 disclosures) for SNY.

SNY screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas SNY trades at 8.9x Forward P/E, 24.1x Trailing P/E, 1.76x PEG, and 3.9x EV/Revenue (29.0% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus SNY (5.7% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, SNY carries 22.0% implied volatility (43rd %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.20β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.